This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
Levity para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A cash-pay brand-medication program currently covering 35 listed states. Consultation, prescription, medication, shipping, monthly tracking, follow-ups, and unlimited clinical support are bundled, but the page contains a broad “from $179” promotion alongside brand-specific totals of $1,149–$1,599.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)
- Formats reviewed
- Injection
- Funding routes
- Private pay
- Service features
- Clinician support · Switching pathway · Home delivery
- Access check
- Provider coverage published; confirm treatment
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 3 medicine rows · 4 open checks
Recurring cost breakdown
- Mounjaro: $1,249 first month with code, then $1,299 every four weeks.
- Wegovy: $1,549 first month with code, then $1,599 every four weeks.
- Ozempic: $1,149 first month with code, then $1,199 every four weeks.
- Consultation, prescription, medication, shipping, follow-ups, and unlimited clinical support are described as included.
- A separate “from $179/month” statement is unresolved without completing eligibility and must not be equated with the three brand cards.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Mounjaro | Weekly pen | FDA-approved for type 2 diabetes | $1,249 promo first month; $1,299 thereafter |
| Wegovy | Weekly pen | FDA-approved for weight management | $1,549 promo first month; $1,599 thereafter |
| Ozempic | Weekly pen | FDA-approved for type 2 diabetes | $1,149 promo first month; $1,199 thereafter |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- The page lists 35 states: AK, CO, CT, FL, GA, HI, IL, IN, IA, KY, ME, MD, MA, MI, MN, MO, MT, NE, NV, NJ, NY, ND, OH, OK, OR, PA, RI, SD, TN, TX, VT, VA, WA, WI, and WY.
- The remaining states and D.C. were not listed at review.
Clinician access and follow-up cadence
- US-based clinical review precedes prescribing.
- Progress is tracked monthly.
- Follow-up appointments and unlimited clinical support are included; support hours are published as Monday–Friday, 9 a.m.–5 p.m. Eastern.
Pharmacy and fulfillment
- Medication is billed and shipped approximately every four weeks.
- The public page does not name the dispensing pharmacy.
Insurance and prior authorization
- The displayed program prices are cash totals.
- An insurance prior-authorization path is not central to the reviewed offer.
Cancellation, refund, and commitment
- Each brand card says cancel anytime.
- Confirm the cutoff before the next four-week prescription shipment and refund eligibility after pharmacy processing.
Labs, monitoring, and dose management
- A universal included laboratory panel was not published.
- Monthly progress review is advertised, with testing left to clinical judgment.
Maintenance and switching
- Monthly tracking and ongoing support can support maintenance.
- An existing dose requires new review; no public transfer-continuity guarantee was found.
Program snapshot
Bundled brand-medication program
Profiled support: Ongoing clinician access, Simplified intake and fulfillment.
Cash pay
The reviewed route is direct cash pay.
Verify before purchase
The source advertises shipped brand-name medication. Confirm the dispensing pharmacy and exact state availability.
What the advertised program may include
- Online intake
- Clinician review
- Medication when prescribed
- Digital follow-up
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
- Simplified intake and fulfillment
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- What the $179 offer includes
- Named pharmacy
- Universal lab schedule
- Access outside the 35 listed states
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Current brand prices, inclusions, state list, support cadence and cancellation claim
Subscription, billing and service terms